Cathepsin L-induced Galectin-1 May Act As a Proangiogenic Factor in the Metastasis of High-grade Serous Carcinoma
Overview
General Medicine
Authors
Affiliations
Background: New treatment options for metastasised high-grade serous carcinoma (HGSC) are urgently needed. HGSC frequently metastasises to the omentum, inducing angiogenesis in the local omental microvasculature to facilitate tumour growth. We previously showed that HGSC-secreted cathepsin L (CathL) induces pro-angiogenic changes in disease relevant human omental microvascular endothelial cells (HOMECs), suggesting a role in tumour angiogenesis. Here we investigate whether CathL acts by inducing local production of the carbohydrate-binding protein galectin-1 (Gal1), which has been reported to be involved in tumourigenesis in other tumours.
Methods: HOMECs were used for all experiments. Gal1 mRNA and protein levels were measured by RT-PCR and ELISA respectively. Gal1-induced cell proliferation was assessed using WST-1 assay, migration using a transwell assay and in vivo Gal1 expression by immunohistochemistry.
Results: CathL transcriptionally regulated HOMEC production and secretion of Gal1 via activation of NFκB (significantly inhibited by sulfasalazine). Gal1 significantly enhanced HOMEC migration (p < 0.001) and proliferation (p < 0.001), suggesting an autocrine action. The latter was significantly reduced by the MEK/ERK1/2 inhibitors U0126 and PD98059 suggesting downstream activation of this pathway. Immunohistochemical analysis of omenta from HGSC patients with or without metastatic disease demonstrated a positive correlation between Gal1 expression and number of microvessels (r = 0.8702, p < 0.001), and area of vessels (r = 0.7283, p < 0.001), supporting a proangiogenic role for Gal1 in omental metastases.
Conclusion: HOMEC Gal1 transcription and release in response to CathL secreted from metastasising HGSC acts in an autocrine manner on the local microvasculature to induce pro-angiogenic changes, highlighting a potential new therapeutic target.
Obesity-driven changes in breast tissue exhibit a pro-angiogenic extracellular matrix signature.
Bamberg E, Maslanka M, Vinod-Paul K, Sams S, Pollack E, Conklin M Matrix Biol Plus. 2024; 24:100162.
PMID: 39380725 PMC: 11460480. DOI: 10.1016/j.mbplus.2024.100162.
The Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities.
Garlisi B, Lauks S, Aitken C, Ogilvie L, Lockington C, Petrik D Curr Oncol. 2024; 31(7):3826-3844.
PMID: 39057155 PMC: 11275383. DOI: 10.3390/curroncol31070283.
Vascular galectins in tumor angiogenesis and cancer immunity.
Thijssen V Semin Immunopathol. 2024; 46(1-2):3.
PMID: 38990363 PMC: 11239785. DOI: 10.1007/s00281-024-01014-9.
Li L, Quan J, Liu H, Yu H, Chen H, Xia C BMC Genomics. 2024; 25(1):17.
PMID: 38166615 PMC: 10759622. DOI: 10.1186/s12864-023-09928-8.
Lysosomes, curcumin, and anti-tumor effects: how are they linked?.
Shen Q, Pan X, Li Y, Li J, Zhang C, Jiang X Front Pharmacol. 2023; 14:1220983.
PMID: 37484013 PMC: 10359997. DOI: 10.3389/fphar.2023.1220983.